Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2

Manuscript Number: 

21-0201R2

Author(s): 
Paul Aisen, Bruce Albala, Chris J. Edgar, Paul Maruff, Ronald C. Petersen, Eric Siemers, Michael W. Weiner

Disclosures

Paul Aisen

  • Consulting Fees:
    Consulting fees from Merck, Biogen, Roche, ImmunoBrain Checkpoint, Abbvie, Rainbow Medical, Shionogi.
    Grants
    • Agency: 
      Research agreements with Lilly and Eisai
      Dates: 
      2012-present

Bruce Albala

  • Nothing to Disclose

Chris J. Edgar

  • Nothing to Disclose

Paul Maruff

  • Sponsors:
    Paul Maruff is a full time employee of Cogstate Ltd

Ronald C. Petersen

  • Consulting Fees:
    Roche, Merck, Biogen, Genentech
    Patents/Royalties
    Royalties: Oxford University Press, UpTodate

Eric Siemers

  • Consulting Fees:
    Cogstate Ltd (consultant) Gates Ventures (consultant) Vaccinex Inc. (consultant) Cortexyme Scientific Advisory Board (2019-2021) Luminds Scientific Advisory Board (2018 - current) Green Valley Scientific Advisory Board (2020 - current)
    Equity:
    Acumen Pharmaceuticals (stock options)

Michael W. Weiner

  • Consulting Fees:
    Dr. Weiner has performed Paid Consulting on Advisory Boards for: Alzheon, Inc., Biogen, Cerecin, Dolby Family Ventures, Eli Lilly, Merck Sharp & Dohme Corp., Nestle/Nestec, and Roche, T3D Therapeutics, University of Southern California (USC). He has provided Paid Consulting to: Baird Equity Capital, BioClinica, Cerecin, Inc., Cytox, Dolby Family Ventures, Duke University, FUJIFILM-Toyama Chemical (Japan), Garfield Weston, Genentech, Guidepoint Global, Indiana University, Japanese Organization for Medical Device Development, Inc. (JOMDD), Nestle/Nestec, NIH, Peerview Internal Medicine, Roche, T3D Therapeutics, University of Southern California (USC), and Vida Ventures.
    Equity:
    Dr. Weiner holds stock options with Alzheon, Inc. Alzeca, and Anven
    Grants
    • Agency: 
      Johnson & Johnson
      Dates: 
      4/2014-present